BRD4 and acute myeloid leukemia: Importantly, the BRD4 BD2 domain inhibitor ABBV-744, which shows much less toxicity to normal tissues in preclinical models, has also entered a Phase I clinical trial in relapsed or refractory acute myeloid leukemia patients.